1. Vanderpump MPJ, Tunbridge WMG.
The epidemiology of thyroid diseases.
In: Braverman LE, Utiger RD, eds. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text.
7th ed. Philadelphia, Pa: Lippincott-Raven; 1996.
2. Tunbridge WM, Evered DC, Hall R, et al.
The spectrum of thyroid disease in a community: the Whickham Survey.
Clin Endocrinol (Oxf). 1977;7:481-493.
3. Vanderpump MP, Tunbridge WM, French JM, et al.
The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey.
Clin Endocrinol (Oxf). 1995;43:55-68.
4. Sawin CT, Castelli WP, Hershman JM, McNamara P, Bacharach P.
The aging thyroid: thyroid deficiency in the Framingham Study.
Arch Intern Med. 1985;145:1386-1388.
5. Bagchi N, Brown TR, Parish RF.
Thyroid dysfunction in adults over age 55 years: a study in an urban US community.
Arch Intern Med. 1990;150:785-787.
6. Singer PA, Cooper DS, Levy EG, et al.
Treatment guidelines for patients with hyperthyroidism and hypothyroidism.
JAMA. 1995;273:808-812.
7. Klee GG, Hay ID.
Biochemical testing of thyroid function.
Endocrinol Metab Clin North Am. 1997;26:763-775.
8. Rosenthal MJ, Hunt WC, Garry PJ, Goodwin JS.
Thyroid failure in the elderly: microsomal antibodies as discriminant for therapy.
JAMA. 1987;258:209-213.
9. Tanis BC, Westendorp GJ, Smelt HM.
Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a
reanalysis of intervention studies.
Clin Endocrinol (Oxf). 1996;44:643-649.
10. Arem R, Patsch W.
Lipoprotein and apolipoprotein levels in subclinical hypothyroidism: effect of levothyroxine therapy.
Arch Intern Med. 1990;150:2097-2100.
11. Staub JJ, Althaus BU, Engler H, et al.
Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve,
and metabolic impact on peripheral target tissues.
Am J Med. 1992;92:631-642.
12. Franklyn JA, Daykin J, Betteridge J, et al.
Thyroxine replacement therapy and circulating lipid concentrations.
Clin Endocrinol (Oxf). 1993;38:453-459.
13. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC.
L-Thyroxine therapy in subclinical hypothyroidism: a double-blind, placebo-controlled trial.
Ann Intern Med. 1984;101:18-24.
14. Nystrom E, Caidahl K, Fager G, Wikkelso C, Lundberg PA, Lindstedt G.
A double-blind crossover 12-month study of L-thyroxine treatment of women with "subclinical"
hypothyroidism.
Clin Endocrinol (Oxf). 1988;29:63-76.
15. Jaeschke R, Guyatt G, Gerstein H, et al.
Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical
hypothyroidism?
J Gen Intern Med. 1996;11:744-749.
16. Baldini IM, Vita A, Mauri MC, et al.
Psychopathological and cognitive features in subclinical hypothyroidism.
Prog Neuropsychopharmacol Biol Psychiatry. 1997;21:925-935.
17. Sawin CT, Geller A, Wolf PA, et al.
Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.
N Engl J Med. 1994;331:1249-1252.
18. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY.
Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis.
J Clin Endocrinol Metab. 1996;81:4278-4289.
19. Faber J, Galloe AM.
Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a
meta-analysis. Eur J Endocrinol. 1994;130:350-356.
20. Biondi B, Fazio S, Carella C, et al.
Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long
term suppressive therapy with levothyroxine.
J Clin Endocrinol Metab. 1994;78:1028-1033.
21. Spencer CA, Takeuchi M, Kazarosyan M.
Current status and performance goals for serum thyrotropin (TSH) assays.
Clin Chem. 1996;42:140-145.
22. Danese MD, Powe NR, Sawin CT, Ladenson PW.
Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness
analysis. JAMA. 1996;276:285-292.
23. Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force. 2nd ed.
Baltimore, Md: Williams & Wilkins; 1995.